

September 8, 2026

**BrightPath to Present Preclinical Data of
iPSC-Derived BCMA CAR-iNKT Cell Therapy (BP2202) at IMS 2026**

TOKYO, Japan, September 8, 2026/ — BrightPath Biotherapeutics Co., Ltd. (TSE Growth: 4594), a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics, today announced that the Company will present preclinical data on BP2202, an allogeneic, iPSC-derived BCMA CAR-iNKT cell therapy, at the International Myeloma Society Annual Meeting 2026 (“IMS 2026”), to be held in Glasgow, United Kingdom, from September 23 to 26, 2026.

IMS 2026 is one of the world's leading scientific conferences in multiple myeloma, featuring the latest findings across basic research, preclinical and clinical development. More than 3,000 researchers and healthcare professionals from around the world are expected to attend this year.

BrightPath has initiated a Phase 1 clinical trial of BP2202 in the United States, following authorization from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application to proceed. In addition to preclinical data for BP2202 in multiple myeloma, BrightPath will also present the design of the Phase 1 clinical trial at the meeting.

[Presentation Details]

Abstract Number: PA-058

Title: BP2202: An Off-the-Shelf iPSC-Derived BCMA-Targeted Cellular Therapy for Multiple Myeloma

Meeting Dates: September 23–26, 2026

About BP2202:

BP2202 is an allogeneic, off-the-shelf cell therapy derived from induced pluripotent stem cells (iPSCs) and engineered to express a chimeric antigen receptor targeting B cell maturation antigen (BCMA). By combining an iPSC-derived manufacturing platform with invariant natural killer T (iNKT) cells, BP2202 is designed to provide a readily available treatment option for patients with multiple myeloma. BP2202 is currently being evaluated in a Phase 1 clinical trial in the United States.

About BrightPath Biotherapeutics:

BrightPath (Tokyo Stock Exchange Growth: 4594) is a clinical-stage biopharmaceutical company focused on the development of novel cancer therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies, currently in clinical trials, and immunomodulatory antibodies.

Forward-Looking Statements:

This press release contains forward-looking statements concerning the development of BP2202, including the design and conduct of clinical trials and the potential therapeutic benefits of the product candidate. These statements are based on management's current assumptions and are subject to risks and uncertainties inherent in preclinical and clinical development, regulatory review, manufacturing, competition and financing. Actual results may differ materially. BrightPath undertakes no obligation to update these statements except as required by law.

Investor and Media Contact:

Administration Department,
BrightPath Biotherapeutics Co., Ltd.

E-mail: irpr@brightpathbio.com

<https://www.brightpathbio.com/English/>